Innventure, Inc. - Common Stock (INV)

Recent filings reveal a flurry of insider selling activities across diverse sectors, drawing investor attention to transactions at major players like Lam Research (NASDAQ: LRCX), the innovative Serina Therapeutics (NASDAQ: SER), emerging firm Innventure (NASDAQ: INV), and the established Smiths Group (LON: SMIN). These divestments, ranging from routine tax-related sales

U.S. stock futures rose on Wednesday after a volatile session on Tuesday. Futures of all benchmark indices advanced in premarket trading.

Innventure Inc (NASDAQ: INV) has an early-stage portfolio with high growth potential, according to Roth Capital. Analyst Chip Moore rates it a Buy with a $16 target.